Severity of allergic rhinitis assessed by using urine metabolomic profiling: Proof of concept - 04/08/18
Doi : 10.1016/j.jaci.2018.02.051
Darryl J. Adamko, MD, FRCPC a, b, c 
, Mona M. Khamis, MSc c, Lisa M. Steacy, BSc, CCRP e, Shana Regush, BSc a, Rhonda Bryce, MD, MSc d, Anne K. Ellis, MD, MSc, FRCPC e, f
, Mona M. Khamis, MSc c, Lisa M. Steacy, BSc, CCRP e, Shana Regush, BSc a, Rhonda Bryce, MD, MSc d, Anne K. Ellis, MD, MSc, FRCPC e, f a Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
b Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
c Department of Pediatrics, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
d Clinical Research Support Unit, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
e Allergy Research Unit, Kingston General Hospital, Kingston, Ontario, Canada
f Department of Medicine, Queen's University, Kingston, Ontario, Canada
| Supported by AllerGen, NCE, the Magnetic Resonance Diagnostic Centre (MRDC), and the Canadian Institutes for Health Research (CIHR). The MRDC has received funding from CIHR, Genome Prairie, Genome Canada, an establishment grant from AHFMR, the Canadian National High Field NMR Centre (NANUC), the Natural Science and Engineering Research Council of Canada (NSERC), the University of Alberta Hospital Foundation, the Alberta Science and Research Authority (ASRA), and Western Economic Development (WED) and was supported in kind by the Allergy Research Trust of the Kingston General Hospital Research Institute. |
|
| Disclosure of potential conflict of interest: D. J. Adamko is CEO of a startup company that someday hopes to see this type of work used in clinical practice but does not have any patents for the data in this letter. A. K. Ellis reports personal fees from AstraZeneca, Aralez, Boehringer Ingelheim, Pediapharm, Novartis, Pfizer, ALK-Abelló, and Merck and also reports grants from Merck, Novartis, and Sanofi-Genzyme outside the submitted work. The rest of authors declare that they have no relevant conflicts of interest. |
© 2018
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 142 - N° 2
P. 687 - août 2018 Retour au numéro
Article précédent
- Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus–induced type 2 responses and immunopathology
- Melissa H. Bloodworth, Mark Rusznak, Connor C. Pfister, Jian Zhang, Lisa Bastarache, Sandra Alvarez Calvillo, James D. Chappell, Kelli L. Boyd, Shinji Toki, Dawn C. Newcomb, Matthew T. Stier, Weisong Zhou, Kasia Goleniewska, Martin L. Moore, Tina V. Hartert, Kevin D. Niswender, R. Stokes Peebles
- A novel human mast cell activation test for peanut allergy
- Alexandra F. Santos, Natália Couto-Francisco, Natalia Bécares, Matthew Kwok, Henry T. Bahnson, Gideon Lack
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?